Telix Historical Balance Sheet

TLX Stock

24.62 0.12 0.49%

Trend analysis of Telix Pharmaceuticals balance sheet accounts such as Property Plant And Equipment Net of 32 M, Accounts Payable of 34.5 M, Cash of 63.5 M or Non Current Assets Total of 182.1 M provides information on Telix Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Telix Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Telix Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Telix Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Telix Pharmaceuticals is a good buy for the upcoming year.

Telix Pharmaceuticals Inventory

18.18 Million

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telix Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Telix Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Telix Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Telix Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Telix Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Telix currently owns. An asset can also be divided into two categories, current and non-current.

Telix Pharmaceuticals Balance Sheet Chart

At this time, Telix Pharmaceuticals' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Total Liabilities is likely to gain to about 261.9 M in 2024, despite the fact that Retained Earnings are likely to grow to (250.5 M).

Common Stock Shares Outstanding Total Assets Total Current Liabilities Total Stockholder Equity

Add Fundamental

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Total Assets

Total assets refers to the total amount of Telix Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Telix Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Telix Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Telix Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Most accounts from Telix Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Telix Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telix Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2021	2022	2023	2024 (projected)
Total Current Liabilities	38.0M	85.6M	157.4M	165.3M
Total Assets	109.8M	260.6M	398.3M	418.2M

Total Current Liabilities Total Assets

Telix Pharmaceuticals balance sheet Correlations

	Common Stock Shares Outstanding	Total Assets	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Short Long Term Debt Total	Other Current Liab	Other Liab	Net Tangible Assets	Non Currrent Assets Other	Other Assets	Good Will	Inventory
Common Stock Shares Outstanding		0.74	0.66	0.53	0.61	-0.62	-0.84	0.72	0.68	0.76	0.68	0.74	0.92	0.93	0.77	0.62	0.69	0.77	0.65	0.64	0.86	-0.7	-0.24	0.64	0.94	0.61
Total Assets	0.74		0.98	0.9	0.96	-0.84	-0.91	0.98	0.73	0.98	0.73	0.99	0.88	0.79	0.98	0.96	0.98	0.99	0.98	0.98	0.92	-0.39	0.17	0.94	0.75	0.97
Total Current Liabilities	0.66	0.98		0.85	0.99	-0.77	-0.91	0.99	0.65	0.97	0.65	0.99	0.82	0.75	0.98	0.99	0.96	0.98	1.0	1.0	0.9	-0.41	0.17	0.96	0.69	1.0
Total Stockholder Equity	0.53	0.9	0.85		0.81	-0.87	-0.66	0.83	0.74	0.84	0.74	0.84	0.68	0.52	0.79	0.81	0.92	0.83	0.87	0.85	0.67	-0.03	0.34	0.83	0.54	0.85
Property Plant And Equipment Net	0.61	0.96	0.99	0.81		-0.74	-0.91	0.97	0.63	0.95	0.63	0.98	0.79	0.75	0.97	1.0	0.94	0.96	0.99	0.99	0.88	-0.36	0.19	0.95	0.67	0.98
Net Debt	-0.62	-0.84	-0.77	-0.87	-0.74		0.74	-0.73	-0.93	-0.72	-0.93	-0.76	-0.71	-0.65	-0.77	-0.74	-0.92	-0.84	-0.8	-0.79	-0.7	0.03	-0.34	-0.8	-0.55	-0.76
Retained Earnings	-0.84	-0.91	-0.91	-0.66	-0.91	0.74		-0.92	-0.69	-0.91	-0.69	-0.94	-0.92	-0.93	-0.97	-0.91	-0.89	-0.96	-0.9	-0.9	-0.97	0.6	0.02	-0.89	-0.84	-0.88
Accounts Payable	0.72	0.98	0.99	0.83	0.97	-0.73	-0.92		0.61	0.98	0.61	1.0	0.87	0.78	0.98	0.98	0.94	0.97	0.98	0.98	0.92	-0.49	0.05	0.93	0.75	0.98
Cash	0.68	0.73	0.65	0.74	0.63	-0.93	-0.69	0.61		0.61	1.0	0.65	0.64	0.7	0.67	0.63	0.8	0.74	0.68	0.67	0.63	-0.01	0.29	0.7	0.55	0.63
Non Current Assets Total	0.76	0.98	0.97	0.84	0.95	-0.72	-0.91	0.98	0.61		0.61	0.98	0.9	0.81	0.98	0.95	0.92	0.96	0.96	0.95	0.94	-0.52	0.08	0.9	0.81	0.94
Cash And Short Term Investments	0.68	0.73	0.65	0.74	0.63	-0.93	-0.69	0.61	1.0	0.61		0.65	0.64	0.7	0.67	0.63	0.8	0.74	0.68	0.67	0.63	-0.01	0.29	0.7	0.55	0.63
Net Receivables	0.74	0.99	0.99	0.84	0.98	-0.76	-0.94	1.0	0.65	0.98	0.65		0.88	0.8	0.99	0.98	0.96	0.99	0.99	0.98	0.93	-0.47	0.09	0.95	0.77	0.98
Common Stock Total Equity	0.92	0.88	0.82	0.68	0.79	-0.71	-0.92	0.87	0.64	0.9	0.64	0.88		0.92	0.91	0.79	0.83	0.9	0.8	0.8	0.97	-0.69	-0.17	0.74	0.91	0.78
Non Current Liabilities Total	0.93	0.79	0.75	0.52	0.75	-0.65	-0.93	0.78	0.7	0.81	0.7	0.8	0.92		0.86	0.75	0.75	0.84	0.73	0.73	0.94	-0.67	-0.1	0.72	0.91	0.7
Total Liab	0.77	0.98	0.98	0.79	0.97	-0.77	-0.97	0.98	0.67	0.98	0.67	0.99	0.91	0.86		0.97	0.95	0.99	0.97	0.97	0.97	-0.53	0.09	0.93	0.8	0.96
Property Plant And Equipment Gross	0.62	0.96	0.99	0.81	1.0	-0.74	-0.91	0.98	0.63	0.95	0.63	0.98	0.79	0.75	0.97		0.94	0.96	0.99	0.99	0.89	-0.38	0.18	0.95	0.67	0.99
Total Current Assets	0.69	0.98	0.96	0.92	0.94	-0.92	-0.89	0.94	0.8	0.92	0.8	0.96	0.83	0.75	0.95	0.94		0.98	0.97	0.97	0.87	-0.27	0.25	0.95	0.68	0.95
Common Stock	0.77	0.99	0.98	0.83	0.96	-0.84	-0.96	0.97	0.74	0.96	0.74	0.99	0.9	0.84	0.99	0.96	0.98		0.98	0.97	0.95	-0.45	0.11	0.95	0.79	0.96
Short Long Term Debt Total	0.65	0.98	1.0	0.87	0.99	-0.8	-0.9	0.98	0.68	0.96	0.68	0.99	0.8	0.73	0.97	0.99	0.97	0.98		1.0	0.88	-0.35	0.2	0.97	0.69	0.99
Other Current Liab	0.64	0.98	1.0	0.85	0.99	-0.79	-0.9	0.98	0.67	0.95	0.67	0.98	0.8	0.73	0.97	0.99	0.97	0.97	1.0		0.88	-0.36	0.2	0.96	0.66	1.0
Other Liab	0.86	0.92	0.9	0.67	0.88	-0.7	-0.97	0.92	0.63	0.94	0.63	0.93	0.97	0.94	0.97	0.89	0.87	0.95	0.88	0.88		-0.68	-0.05	0.84	0.89	0.86
Net Tangible Assets	-0.7	-0.39	-0.41	-0.03	-0.36	0.03	0.6	-0.49	-0.01	-0.52	-0.01	-0.47	-0.69	-0.67	-0.53	-0.38	-0.27	-0.45	-0.35	-0.36	-0.68		0.5	-0.3	-0.69	-0.36
Non Currrent Assets Other	-0.24	0.17	0.17	0.34	0.19	-0.34	0.02	0.05	0.29	0.08	0.29	0.09	-0.17	-0.1	0.09	0.18	0.25	0.11	0.2	0.2	-0.05	0.5		0.31	-0.24	0.2
Other Assets	0.64	0.94	0.96	0.83	0.95	-0.8	-0.89	0.93	0.7	0.9	0.7	0.95	0.74	0.72	0.93	0.95	0.95	0.95	0.97	0.96	0.84	-0.3	0.31		0.68	0.95
Good Will	0.94	0.75	0.69	0.54	0.67	-0.55	-0.84	0.75	0.55	0.81	0.55	0.77	0.91	0.91	0.8	0.67	0.68	0.79	0.69	0.66	0.89	-0.69	-0.24	0.68		0.63
Inventory	0.61	0.97	1.0	0.85	0.98	-0.76	-0.88	0.98	0.63	0.94	0.63	0.98	0.78	0.7	0.96	0.99	0.95	0.96	0.99	1.0	0.86	-0.36	0.2	0.95	0.63

Click cells to compare fundamentals

Telix Pharmaceuticals Account Relationship Matchups

Telix Pharmaceuticals balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	233.4M	257.3M	282.2M	310.6M	323.7M	221.8M
Total Assets	102.6M	164.4M	109.8M	260.6M	398.3M	418.2M
Total Current Liabilities	10.6M	20.0M	38.0M	85.6M	157.4M	165.3M
Total Stockholder Equity	70.1M	79.0M	2.2M	80.0M	148.9M	156.4M
Property Plant And Equipment Net	1.9M	4.8M	6.3M	18.8M	30.5M	32.0M
Net Debt	(42.5M)	(75.7M)	(19.5M)	(105.9M)	(105.8M)	(100.5M)
Retained Earnings	(48.1M)	(93.0M)	(173.5M)	(272.8M)	(263.7M)	(250.5M)
Accounts Payable	7.0M	5.8M	11.9M	16.8M	32.8M	34.5M
Cash	44.6M	77.9M	22.0M	116.3M	123.2M	63.5M
Non Current Assets Total	43.9M	70.8M	62.3M	87.4M	173.5M	182.1M
Cash And Short Term Investments	44.6M	77.9M	22.0M	116.3M	123.2M	63.5M
Net Receivables	13.0M	14.2M	20.8M	39.4M	64.8M	68.0M
Liabilities And Stockholders Equity	102.6M	164.4M	109.8M	260.6M	398.3M	418.2M
Non Current Liabilities Total	21.3M	64.5M	68.2M	92.9M	92.0M	48.8M
Total Liab	31.9M	84.4M	106.2M	178.4M	249.4M	261.9M
Property Plant And Equipment Gross	1.9M	4.8M	8.4M	22.2M	36.3M	38.1M
Total Current Assets	58.7M	93.6M	47.5M	173.2M	224.8M	236.1M
Common Stock	115.9M	167.1M	170.8M	371.0M	446.3M	468.6M
Short Long Term Debt Total	2.1M	2.2M	2.5M	10.4M	17.4M	18.3M
Other Current Liab	3.2M	10.1M	19.3M	55.8M	100.5M	105.5M
Other Liab	20.3M	57.4M	67.8M	80.0M	92.0M	96.6M
Net Tangible Assets	28.1M	19.8M	(53.6M)	21.0M	18.9M	10.2M
Non Currrent Assets Other	(4.1M)	183K	(3.9M)	327K	586K	615.3K
Other Assets	82K	183K	212K	4.0M	4.6M	4.8M
Long Term Debt Total	1.6M	1.4M	1.9M	9.8M	11.3M	11.8M
Inventory	542K	633K	3.5M	8.5M	17.3M	18.2M
Other Current Assets	530K	859K	1.2M	9.1M	19.5M	20.5M
Other Stockholder Equity	2.2M	4.9M	4.8M	(562K)	(1.0)	(0.95)
Net Invested Capital	70.8M	79.4M	2.2M	83.3M	158.1M	166.0M
Short Long Term Debt	469K	264K	19K	964K	867.6K	911.0K
Accumulated Other Comprehensive Income	2.2M	4.9M	4.8M	(18.2M)	(33.7M)	(32.0M)
Net Working Capital	48.1M	73.7M	9.6M	87.7M	67.4M	56.9M
Short Term Debt	490K	767K	632K	641K	1.6M	874.9K
Intangible Assets	41.9M	59.2M	55.7M	59.0M	104.8M	56.3M
Property Plant Equipment	1.9M	4.8M	6.3M	18.8M	21.7M	22.7M
Long Term Debt	292K	95K	0.0	3.3M	8.2M	8.6M
Capital Stock	115.9M	167.1M	170.8M	371.0M	446.3M	246.2M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Telix Stock Analysis

When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC